Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Feb 23;103(8):e36897.
doi: 10.1097/MD.0000000000036897.

Association between CCL5, CCL11, and CCL17 polymorphisms and atopic dermatitis risk: A systematic review and meta-analysis

Chenghui Zou  1 , Wen Zhang  1 , Mao Li  2 , Dan He  1 , Yujie Han  1 , Min Liu  2 , Mao Lu  2
Affiliations
Meta-Analysis

Association between CCL5, CCL11, and CCL17 polymorphisms and atopic dermatitis risk: A systematic review and meta-analysis

Chenghui Zou et al. Medicine (Baltimore). .

Abstract

Background: Atopic dermatitis (AD) is a common and recurrent inflammatory disease with strong genetic susceptibility. The abnormal production of chemokines plays an important role in the occurrence and development of AD.

Methods: A comprehensive online literature search was performed in databases of China National Knowledge Infrastructure, Wanfang, VIP China Science and Technology Journal Database, China Biomedical Literature Database, PubMed, Embase and Cochrane Library to retrieve relevant articles published from January 2000 to October 2022. The odds ratio (OR) with its 95% confidence interval (CI) was employed to calculate this relationship.

Results: A total of 7 studies were finally screened out, including 1316 AD patients and 1099 controls. There were 3 studies for CC chemokine ligand 5 (CCL5) polymorphisms, 2 for CCL11 polymorphisms, and 2 for CCL17 polymorphisms, respectively. The meta-analysis revealed a significant association between the CCL5 - 403G/A polymorphism and AD under the allelic model (A vs G: OR = 1.25, 95% CI = 1.02-1.52, P = .03), heterozygous model (AG vs GG: OR = 1.40, 95% CI = 1.08-1.80, P = .01) and dominant model (AA + AG vs GG: OR = 1.38, 95% CI = 1.08-1.76, P = .01) in a fixed-effect model. The allelic model (G vs C: OR = 1.46, 95% CI = 1.07-1.98, P < .01) and dominant model (GG + GC vs CC: OR = 1.74, 95% CI = 1.23-2.47, P < .001) of the CCL5 - 28C/G polymorphism were also associated with an increased risk of AD. However, this significant association was not found in other alleles and genotypes (P > .05).

Conclusion: Our results show that the A allele, AG and AA + AG genotypes of the CCL5 - 403G/A polymorphism, the G allele and GG + GC genotype of the CCL5 - 28C/G polymorphism are risk factors for AD. Future studies with large population are still needed to further explore those correlations.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1.
Figure 1.
Flow diagram of the study selection process.
Figure 2.
Figure 2.
Association between the CCL5 − 403G/A polymorphism and AD risk in the allelic model. AD = atopic dermatitis, CCL = CC chemokine ligand.
Figure 3.
Figure 3.
Association between the CCL5 − 28C/G polymorphism and AD risk in the allelic model. AD = atopic dermatitis, CCL = CC chemokine ligand.
Figure 4.
Figure 4.
Association between the CCL11 − 426C/T polymorphism and AD risk in the allelic model. AD = atopic dermatitis, CCL = CC chemokine ligand.
Figure 5.
Figure 5.
Association between the CCL11 − 67G/A polymorphism and AD risk in the allelic model. AD = atopic dermatitis, CCL = CC chemokine ligand.
Figure 6.
Figure 6.
Association between the CCL11 − 384A/G polymorphism and AD risk in the allelic model. AD = atopic dermatitis, CCL = CC chemokine ligand.
Figure 7.
Figure 7.
Association between the CCL17 − 431C/T polymorphism and AD risk in the allelic model. AD = atopic dermatitis, CCL = CC chemokine ligand.
See this image and copyright information in PMC

References

    1. Sabin BR, Peters N, Peters AT. Chapter 20: atopic dermatitis. Allergy Asthma Proc. 2012;33(Suppl 1):67–9. - PubMed
    1. Jordan HF, Todd G, Sinclair W, et al. Aetiopathogenesis of atopic dermatitis. S Afr Med J. 2014;104:706–9. - PubMed
    1. Mancini AJ, Kaulback K, Chamlin SL. The socioeconomic impact of atopic dermatitis in the United States: a systematic review. Pediatr Dermatol. 2008;25:1–6. - PubMed
    1. Williams H, Flohr C. How epidemiology has challenged 3 prevailing concepts about atopic dermatitis. J Allergy Clin Immunol. 2006;118:209–13. - PubMed
    1. Flohr C, Mann J. New insights into the epidemiology of childhood atopic dermatitis. Allergy. 2014;69:3–16. - PubMed